Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520751 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
A Phase 1 study, sponsored by Nationwide Children's Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03520751 is a Phase 1 study that has not yet begun recruiting, run by Nationwide Children's Hospital. The registered enrollment target is 3 participants.
The verdict
NCT03520751, a Phase 1 study, has not yet begun recruiting, sponsored by Nationwide Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This clinical trial is an open-label one-time injection dose study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into muscles in both legs in CMT1A subjects with PMP22 gene duplication. Three subjects ages 18 to 35 years receiving (8.87e11 vg/kg) will be enrolled.
Interventions
- DRUG scAAV1.tMCK.NTF3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2027-04 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520751
The ClinicalTrials.gov registry entry for NCT03520751 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which scAAV1.tMCK.NTF3 is the first listed.
NCT03520751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520751 about?
NCT03520751 is a clinical study titled "Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A". This clinical trial is an open-label one-time injection dose study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into muscles in both legs in CMT1A subjects with PMP22 gene duplication. Three subjects ages 18 to 35 years receiving (8.87e11 vg/kg) will be enrolled.
What is the current status of trial NCT03520751?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2027-04. Estimated completion is 2030-04.
What interventions are being tested in trial NCT03520751?
The interventions under investigation include: scAAV1.tMCK.NTF3 (DRUG).
Who is sponsoring clinical trial NCT03520751?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.